Therapeutic Advances in Psychopharmacology最新文献

{"title":"Drug safety in older patients with alcohol use disorder: a retrospective cohort study.","authors":"Sebastian Schröder, Martin Schulze Westhoff, Tabea Pfister, Johanna Seifert, Stefan Bleich, Felix Koop, Phileas Johannes Proskynitopoulos, Alexander Glahn, Johannes Heck","doi":"10.1177/20451253241232563","DOIUrl":"10.1177/20451253241232563","url":null,"abstract":"<p><strong>Background: </strong>Older patients with alcohol use disorder are at particular risk of developing adverse drug reactions due to multimorbidity, polypharmacy, and altered organ function.</p><p><strong>Objectives: </strong>In this study, we investigated the frequency and characteristics of potentially serious alcohol-medication interactions, potentially inappropriate medications (PIMs) for older adults, and potential drug-drug interactions (pDDIs) in a population of older patients with alcohol use disorder over a 10-year period.</p><p><strong>Design: </strong>Retrospective monocentric cohort study.</p><p><strong>Methods: </strong>Prescribed medications were screened for potentially serious alcohol-medication interactions, PIMs, and pDDIs using the POSAMINO (POtentially Serious Alcohol-Medication INteractions in Older adults) criteria, the PRISCUS 2.0 list, the FORTA (Fit fOR The Aged) classification, and the drug interaction program AiD<i>Klinik</i>^®.</p><p><strong>Results: </strong>We enrolled 114 patients aged ⩾65 years with alcohol use disorder, who were treated in an addiction unit of a university hospital in Germany. About 80.7% of the study population had at least one potentially serious alcohol-medication interaction. Potentially serious alcohol-medication interactions most commonly affected the cardiovascular (57.7%) and the central nervous system (32.3%). A total of 71.1% of the study population received at least one prescription of a FORTA C or D drug, compared with 42.1% who received at least one PIM prescription according to the PRISCUS 2.0 list. A total of 113 moderate and 72 severe pDDIs were identified in the study population.</p><p><strong>Conclusion: </strong>Older patients with alcohol use disorders are frequently exposed to potentially serious alcohol-medication interactions, PIMs, and pDDIs. Improvements in the quality of prescribing should primarily target the use of cardiovascular and psychotropic drugs.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"14 ","pages":"20451253241232563"},"PeriodicalIF":4.2,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10880528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients' awareness of recovery mediates the link between clinical and level of functional remission in schizophrenia to a larger extent in those treated with long-acting antipsychotics.","authors":"Jasmina Mallet, Clément Dondé, Caroline Dubertret, Philip Gorwood","doi":"10.1177/20451253241231269","DOIUrl":"10.1177/20451253241231269","url":null,"abstract":"<p><strong>Background: </strong>Clinical remission is a step towards functional remission for subjects with schizophrenia. While recovery is both a subjective personal journey and a clinical outcome to be targeted, data on patient self-rated outcomes are scarce.</p><p><strong>Objectives: </strong>(i) To determine the extent to which the association between clinical and functional remission is mediated by the subjective experience of recovery as reported by patients <i>versus</i> their relatives or their psychiatrist and (ii) to assess differences according to treatment, specifically with oral antipsychotics only <i>versus</i> long-acting injectable antipsychotics (LAIs).</p><p><strong>Design: </strong>Clinical observational study.</p><p><strong>Methods: </strong>Community-dwelling participants with schizophrenia enrolled in the EGOFORS cohort (<i>N</i> = 198) were included. Clinical symptoms and remission were assessed using the Positive and Negative Syndrome Scale. Functional remission was assessed with the Functional Remission of General Schizophrenia Scale. Awareness of recovery was assessed with one question 'What percentage of recovery do you think you have now (from 0% - no recovery - to 100% - full recovery)?', asked of the patient, also of the patient's close relative, and the psychiatrist. We used mediation analyses, taking into account the type of pharmacological treatment.</p><p><strong>Results: </strong>Remission criteria and perceived remission measures were significantly correlated, both within and between groups (<i>r</i> > 0.330). The patient's awareness of recovery mediated the relationship between clinical remission and level of functional remission, while the level of recovery according to psychiatrists or close relatives did not. The direct effect of clinical remission on the level of functional remission became non-significant when taking into account the mediator (patients' awareness of recovery) in the group of patients with LAI (<i>t</i> = 1.5, <i>p</i> = 0.150) but not in the group of patients with other treatments (<i>t</i> = 3.1, <i>p</i> = 0.003).</p><p><strong>Conclusion: </strong>Patients with LAIs may be more efficient in reporting their level of functional remission. Higher patient awareness could be an interesting candidate to explain this. However, as the study was cross-sectional, such a proposal should be tested with a more specifically designed protocol, such as a long-term cohort.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"14 ","pages":"20451253241231269"},"PeriodicalIF":4.2,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874148/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139900433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monoclonal antibody precision therapy targeting inflammation for bipolar disorder: a narrative review.","authors":"Shijin Wu, Yuyang Zhou","doi":"10.1177/20451253241227772","DOIUrl":"10.1177/20451253241227772","url":null,"abstract":"<p><p>Bipolar disorder (BD) is a severe mental disorder with various hypotheses regarding its pathogenesis. This article provides a summary of numerous studies on the variations in inflammatory cytokine levels in patients with BD and the effects of treatment with antipsychotics, mood stabilizers, and antidepressants on these levels. In addition, patients with autoimmune diseases who use anti-inflammatory monoclonal antibodies experience symptoms, such as depression, anxiety, and insomnia. These pieces of evidence suggest a potential association between immune inflammation and BD and offer new possibilities for therapy. Building upon this relationship, the authors propose an innovative approach for treating BD through individualized and precise therapy using anti-inflammatory monoclonal antibody drugs. To support this proposal, the authors compile information on pharmacological effects and relevant studies, including trials of various anti-inflammatory therapeutic monoclonal antibody drugs (e.g. infliximab, tocilizumab, and canakinumab) for the potential treatment of BD and its associated side effects in psychiatry. The authors categorize these anti-inflammatory monoclonal antibody drugs into levels I-IV through a comprehensive analysis of their advantages and disadvantages. Their potential is examined, and the need for further exploration of their pharmaceutical effects is established.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"14 ","pages":"20451253241227772"},"PeriodicalIF":4.2,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10846009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139698394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Managing medical and psychiatric multimorbidity in older patients\".","authors":"","doi":"10.1177/20451253241227940","DOIUrl":"https://doi.org/10.1177/20451253241227940","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/20451253231195274.].</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"14 ","pages":"20451253241227940"},"PeriodicalIF":4.2,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10798067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139513346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to “History repeating: guidelines to address common problems in psychedelic science”","authors":"","doi":"10.1177/20451253231223609","DOIUrl":"https://doi.org/10.1177/20451253231223609","url":null,"abstract":"","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"90 3","pages":""},"PeriodicalIF":4.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139454414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary data from a 4-year mirror-image and multicentre study of patients initiating paliperidone palmitate 6-monthly long-acting injectable antipsychotic: the Paliperidone 2 per Year study.","authors":"Juan Antonio García-Carmona, Alba García-Pérez, Guillermo Isidro García, Luis Alberto Forcen-Muñoz, Santiago Ovejero García, Rocío Sáez Povedano, Ana Luisa González-Galdámez, Laura Mata Iturralde, Fernando Hernández-Sánchez, Mariluz Ramirez Bonilla, Paloma Fuentes-Pérez, Claudia Ovejas-Catalán, Paula Suárez-Pinilla, Francisco Valdivia-Muñoz, Blanca Fernández Abascal, Miguel Omaña Colmenares, Ángela de Lourdes Martín-Pérez, María Pilar Campos-Navarro, Enrique Baca-García, Sergio Benavente-López, Alberto Raya Platero, Miguel Barberán Navalón, Sergio Sánchez-Alonso, Javier Vázquez-Bourgon, Sofia Pappa","doi":"10.1177/20451253231220907","DOIUrl":"10.1177/20451253231220907","url":null,"abstract":"<p><strong>Background: </strong>Paliperidone palmitate 6-monthly (PP6M) is the first long-acting antipsychotic injectable (LAI) to allow for only two medication administrations per year, though there is presently limited insight into its effectiveness and potential added value in real clinical practice conditions.</p><p><strong>Objectives: </strong>To present our ongoing study and draw its preliminary data on patient characteristics initiating PP6M and adherence during the first year of treatment.</p><p><strong>Methods: </strong>The paliperidone 2 per year (P2Y) study is a 4-year, multicentre, prospective mirror-image pragmatic study taking place at over 20 different sites in Europe. The mirror period covers 2 years either side of the PP6M LAI initiation. Retrospective data for the previous 2 years are collected for each patient from the electronic health records. Prospective data are recorded at baseline, 6, 12, 18 and 24 months of drug administration and also cover information on concomitant psychiatric medication, relapses, hospital admissions, side effects, discontinuation and its reasons. Meanwhile, here we present preliminary data from the P2Y study at basal and 6-month period (first and second PP6M administration).</p><p><strong>Results: </strong>At the point of PP6M initiation, the most frequent diagnosis was schizophrenia (69%), the clinical global impression scale mean score was 3.5 (moderately markedly ill) and the rate of previous hospital admissions per patient and year was 0.21. PP6M was initiated after a median of 3-4 years on previous treatment: 146 (73%) from paliperidone palmitate 3-monthly, 37 (19%) from paliperidone palmitate 1-monthly and 17 (9%) from other antipsychotics. The mean dose of the first PP6M was 1098.9 mg. The retention rate at 6 months and 1 year of treatment on PP6M in our cohort was 94%.</p><p><strong>Conclusion: </strong>Patient and clinician preference for LAIs with longer dosing intervals was the main reason for PP6M initiation/switching resulting in high treatment persistence. Future data are needed to evaluate the full impact of PP6M in clinical practice.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"13 ","pages":"20451253231220907"},"PeriodicalIF":4.2,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10752040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral and long-acting injectable antipsychotic discontinuation and relationship to side effects in people with first episode psychosis: a longitudinal analysis of electronic health record data.","authors":"Rashmi Patel, Aimee Brinn, Jessica Irving, Jaya Chaturvedi, Shanmukha Gudiseva, Christoph U Correll, Paolo Fusar-Poli, Philip McGuire","doi":"10.1177/20451253231211575","DOIUrl":"10.1177/20451253231211575","url":null,"abstract":"<p><strong>Background: </strong>Discontinuation of treatment in people with first episode psychosis (FEP) is common, but the extent to which this is related to specific adverse effects of antipsychotic medications is unclear.</p><p><strong>Objectives: </strong>To investigate whether antipsychotic discontinuation is associated with the prescription of particular antipsychotics and particular adverse effects.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Methods: </strong>We assembled de-identified electronic health record (EHR) data from 2309 adults with FEP who received care from the South London and Maudsley NHS Foundation Trust between 1st April 2008 and 31st March 2019. Associations between antipsychotic medications, clinician-recorded side effects and treatment discontinuation were investigated across a mean follow-up period of 34.2 months using Cox regression.</p><p><strong>Results: </strong>The mean age of patients was 26.7 years and 1492 (64.6%) were male. Among first prescribed antipsychotic medications, discontinuation occurred earlier with haloperidol [hazard ratio (HR) = 2.78, 95% CI = 1.69-4.60] and quetiapine (HR = 1.43, 95% CI = 1.16-1.80) than with olanzapine. Discontinuation occurred sooner when there was evidence of extrapyramidal symptoms (HR = 1.33, 95% CI = 1.08-1.64) or sexual dysfunction (HR = 1.59, 95% CI = 1.03-2.46). Among antipsychotics prescribed at any point during treatment, lurasidone (HR = 1.40, 95% CI = 1.10-1.78) and aripiprazole (HR = 1.09, 95% CI = 1.01-1.19) were associated with earlier discontinuation than olanzapine. Conversely, clozapine (HR = 0.55, 95% CI = 0.41-0.73) and paliperidone 1-monthly (PP1M) long-acting injectable (HR = 0.80, 95% CI = 0.68-0.94) were associated with later discontinuation. Unexpectedly, for antipsychotics prescribed at any stage of treatment, sedation (HR = 0.89, 95% CI = 0.81-0.97), weight gain (HR = 0.73, 95% CI = 0.64-0.83), and multiple side effects (HR = 0.83, 95% CI = 0.76-0.90) were associated with later discontinuation.</p><p><strong>Conclusion: </strong>Earlier treatment discontinuation associated with sexual or extrapyramidal side effects could be related to their rapid onset and poor tolerability. Later treatment discontinuation associated with clozapine and PP1M could be related to the relative efficacy of these treatments. These findings merit consideration when selecting antipsychotic therapy for people with FEP.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"13 ","pages":"20451253231211575"},"PeriodicalIF":3.4,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10725124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138805275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and predictors of inappropriate prescribing in outpatients with severe mental illness.","authors":"Lisanne Koomen, Ilona van de Meent, Floor Elferink, Ingeborg Wilting, Wiepke Cahn","doi":"10.1177/20451253231211576","DOIUrl":"https://doi.org/10.1177/20451253231211576","url":null,"abstract":"<p><strong>Background: </strong>Potentially inappropriate prescribing (PIP) is frequent in geriatrics and results in an increased risk for adverse effects, morbidity, mortality and reduced quality of life. Research on PIP in psychiatry has mainly focused on elderly patients and inpatients.</p><p><strong>Objectives: </strong>To determine the prevalence and the predictors of PIP of psychotropic medication in outpatients with severe mental illness.</p><p><strong>Design: </strong>This study is part of the Muva study, a pragmatic open Stepped Wedge Cluster Randomized Trial of a physical activity intervention for patients (age ⩾ 16 years) with severe mental illness.</p><p><strong>Methods: </strong>A structured medication interview, questionnaires on social functioning, quality of life and psychiatric symptoms, and BMI and waist circumference measurements were performed followed by a structured medication review. Patients were divided into groups: PIP <i>versus</i> no PIP. Between-group differences were calculated and a multivariate binary logistic regression was performed to examine predictors for PIP. A receiver operating characteristics analysis was performed to determine the area under the curve (AUC).</p><p><strong>Results: </strong>In 75 patients, an average of 5.2 medications of which 2.5 psychotropic medication was used. 35 (46.7%) patients were identified with PIP. Unindicated long-term benzodiazepine use was the most frequently occurring PIP (34.1%). Predictors of PIP were female gender [odds ratio (OR) = 4.88, confidence interval (CI) = 1.16-20.58, <i>p</i> = 0.03], number of medications (OR = 1.41, CI = 1.07-1.86, <i>p</i> = 0.02) and lower social functioning (OR = 1.42, CI = 1.01-2.00, <i>p</i> = 0.05). The AUC was 0.88 for the combined prediction model.</p><p><strong>Conclusion: </strong>The prevalence of PIP of psychotropic medication in outpatients with severe mental illness is high. It is therefore important to identify, and where possible, resolve PIP by frequently performing a medication review with specific attention to females, patients with a higher number of medications and patients with lower social functioning.</p><p><strong>Trial registration: </strong>This trial was registered in The Netherlands Trial Register (NTR) as NTR NL9163 on 20 December 2020 (https://trialsearch.who.int/Trial2.aspx?TrialID=NL9163).</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"13 ","pages":"20451253231211576"},"PeriodicalIF":4.2,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138462807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults.","authors":"Shen He, Yimin Yu, Jingjing Huang, Jiahui Yin, Yajuan Niu, Yazhou Lu, Bin Wu, Maosheng Fang, Xue Wang, Zhiping Tao, Lehua Li, Kan Li, Yan Li, Xiujuan Ding, Yifeng Shen, Huafang Li","doi":"10.1177/20451253231212342","DOIUrl":"https://doi.org/10.1177/20451253231212342","url":null,"abstract":"<p><strong>Background: </strong>Almost one-third of patients with major depressive disorder (MDD) do not respond to conventional antidepressants, and new treatments for MDD are urgently needed.</p><p><strong>Objectives: </strong>This phase IIb clinical trial was designed to evaluate the efficacy and safety of Anyu Peibo capsules in the treatment of adults with MDD.</p><p><strong>Design: </strong>A multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study.</p><p><strong>Methods: </strong>A total of 172 patients with MDD from nine study centers were randomized (1:1) to receive placebo (<i>n</i> = 86) or oral Anyu Peibo capsules (0.8 g) twice per day (<i>n</i> = 86) for 6 weeks. The primary endpoint was the change in the Montgomery Åsberg Depression Rating Scale (MADRS) total score from baseline to week 6, analyzed using an analysis of covariance (ANCOVA) approach with the baseline MADRS score, center effect and center by group interaction as the covariates. Other efficacy endpoints and variables included clinical response and remission rates according to the MADRS and the 17-item Hamilton Depression Rating Scale (HAMD-17) scores, the change in the HAMD-17, Clinical Global Impression - Severity scale and Clinical Global Impression - Improvement scale scores and the reduction in the Hamilton Anxiety Scale from baseline to week 6.</p><p><strong>Results: </strong>The mean baseline MADRS total scores were 29.20 and 29.72 in the Anyu Peibo (<i>n</i> = 82) and placebo groups (<i>n</i> = 81), respectively. The least squares mean change in the MADRS score from baseline to week 6 was 16.59 points in the Anyu Peibo group and 14.51 points in the placebo group. Although there were greater reductions in the MADRS score from baseline to week 6 in the Anyu Peibo capsule group compared to the placebo group, the difference did not reach statistical significance (least-squares mean difference, 2.07 points; 95% confidence interval, -0.27 to 4.41; <i>p</i> = 0.0819). The results of sensitivity analyses by ANCOVA with the last observation carried forward method for missing data indicated that the administration of Anyu Peibo capsules may lead to a significant reduction in depressive symptoms compared to the placebo (least-squares mean difference: 3.29 points; 95% confidence interval: 0.64-5.93; <i>p</i> = 0.0152). Furthermore, Anyu Peibo capsules showed significant benefits over placebo when the change in the HAMD-17 score from baseline to week 6 was evaluated as the secondary analysis (<i>t</i> = 2.01; 95% confidence interval, 0.03-4.23; <i>p</i> = 0.0464).</p><p><strong>Conclusion: </strong>Anyu Peibo capsules may have an effective and safe antidepressant effect, which warrants further research.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"13 ","pages":"20451253231212342"},"PeriodicalIF":4.2,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138462804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychosocial interventions to improve adherence in depressed and anxious older adults prescribed antidepressant pharmacotherapy: a scoping review.","authors":"Sarah T Stahl, Joelle Kincman, Jordan F Karp, Marie Anne Gebara","doi":"10.1177/20451253231212322","DOIUrl":"https://doi.org/10.1177/20451253231212322","url":null,"abstract":"<p><p>Medication nonadherence in depressed and anxious older adults is prevalent and associated with non-response to antidepressant pharmacotherapy. Evidence-based options to improve medication adherence are limited in this population. To review the state of the literature on the types and efficacy of psychosocial interventions for improving antidepressant pharmacotherapy adherence in depressed and anxious older adults. We conducted a scoping review according to PRISMA-ScR guidelines. PubMed/Medline and article references starting in 1980 up to 28 February 2023 were reviewed. Of the 710 records screened, 4 psychosocial interventions were included in the review. All studies included depressed older adults, and none included anxious older adults. Samples included racial and ethnic minorities and were primarily women. The psychosocial interventions consisted mainly of psychoeducation with usual care as the control comparison. Measures of antidepressant adherence included self-reported adherence or pill counting. Three of the four randomized controlled trials improved medication adherence rates and reduced depression symptom burden. Effective interventions exist for improving antidepressant medication adherence in depressed older adults. Improved adherence can reduce depression symptom burden. The lack of interventions for anxious older adults highlights the need to develop and deliver interventions for anxious older adults prescribed antidepressant pharmacotherapy.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"13 ","pages":"20451253231212322"},"PeriodicalIF":4.2,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138462808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}